Person: TOPÇU, ATAKAN
5 results
Search Results
Now showing 1 - 5 of 5
Publication Metadata only Is There a Relation Between Pretreatment CONUT Score and Neoadjuvant Chemotherapy Response in Breast Cancer Patients?(2022-06-01T00:00:00Z) YASİN, Ayşe İrem; TOPÇU, Atakan; YASİN, AYŞE İREM; TOPÇU, ATAKANObjective: To evaluate the relationship between pre-treatment nutritional status and pathological complete response (pCR) rates in patients with breast cancer.Publication Metadata only Impact of Malnutrition on Prognosis in Patients with HER2-negative Metastatic Gastric Cancer(2022-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; TOPÇU, ATAKAN; YASİN, AYŞE İREMObjective: Malnutrition is common in patients with gastric cancer and may adversely affect their prognosis. This study investigated the impact of malnutrition on overall survival (OS) in patients with metastatic gastric cancer by computing the Malnutrition Universal Screening Tool (MUST), one of the most used nutritional screening tools.Publication Metadata only Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study(2022-04-01T00:00:00Z) GÜRSOY, PINAR; TATLI, ALİ MURAT; Erdem, Dilek; GÖKER, ERDEM; Celik, Emir; Demirci, Nebi Serkan; Sakin, Abdullah; Atci, Muhammed Mustafa; Bayram, Ertugrul; AKIN TELLİ, TUĞBA; Bilgin, Burak; Bilici, Ahmet; Akangunduz, Baran; BALLI, SEVİNÇ; DEMİRKAZIK, AHMET; Selcukbiricik, Fatih; Menekse, Serkan; Cavdar, Eyyup; Ozturk, Akin; Bekmez, Esma Turkmen; Turhal, Serdal; Kilickap, Sadettin; YILDIRIM, HASAN ÇAĞRI; Oyan, Basak; AKSOY, ASUDE; Turkoz, Fatma Paksoy; Kut, Engin; Katgi, Nuran; Sakalar, Teoman; Akyol, Murat; ELLEZ, HALİL İBRAHİM; TOPÇU, Atakan; Erdogan, Atike Pinar; Pilanci, Kezban Nur; Hedem, Engin; Arak, Haci; Akdeniz, Nadiye; Alan, Ozkan; Yapar, Burcu; NART, DENİZ; Yumuk, Perran Fulden; TOPÇU, ATAKANObjectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC). Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323). Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.Publication Metadata only Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma(2022-06-01T00:00:00Z) Shbair, Abdallah T. M.; YASİN, Ayşe İrem; TOPÇU, Atakan; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH; YASİN, AYŞE İREM; TOPÇU, ATAKAN; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİHBesides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.Publication Metadata only A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer(2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMETIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.